World Desk, Press24 News, Beijing
Published by: Dev Kashyap
Updated Wed, 28 Jul 2021 02:12 AM IST
According to laboratory studies, Chinese researchers say that the antibodies produced in most people taking Sinovac Biotech’s Kovid-19 vaccine slow down after about six months. A third dose is necessary to increase the efficacy of the vaccine.
China’s Kovid Vaccine (symbol photo)
– Photo : iStock
hear the news
According to a laboratory study, the antibodies produced in most people taking the Sinovac Biotech (SVA.O) COVID-19 vaccine dropped below a critical threshold about six months after the second dose of the vaccine, although after the third dose. Later, antibodies developed rapidly in people.
Chinese researchers have given this information based on the findings of a study conducted on blood samples of healthy adults aged 18-59 in a paper published on Sunday. However, it has not been peer reviewed.
The paper said that of the people in the study who took two doses of the vaccine, the antibodies formed in 16.9 percent of the people within two weeks and 35.2% within four weeks were inactivated. Researchers believe this on the basis that after six months of taking both doses of the vaccine, the antibodies made to fight the corona slow down. The researchers consider the six-month limit after the second dose as a qualifying level.
The study is based on data from two groups, each consisting of more than 50 participants, compared to a total of 540 participants who were given a third dose of either the vaccine or a placebo. How the shortage will affect the effectiveness of the vaccine, as scientists have yet to figure out the exact range of levels of antibodies to be able to stop the disease.
“In the short- to medium-term, it should be a priority to complete the process of giving two doses of the corona vaccine to as many people as currently possible,” the paper said.
Indonesia and Thailand have already been fully vaccinated with two doses of the Sinovac vaccine, the Moderna and Pfizer vaccine, amid concerns over the vaccine’s effectiveness against the fastest-spreading delta variant of the coronavirus. have agreed to give the third dose of
Disclaimer: This post has been auto-published from an agency/news feed without any modifications to the text and has not been reviewed by an editor.